Jul 23 2004
Curtin University of Technology, Australia has officially launch a groundbreaking tinnitus treatment based on over five years of research.
The launch follows an exhaustive process undertaken by the University in conjunction with a commercial partner to establish Neuromonics Limited, which will deliver the treatment to tinnitus sufferers.
Curtin Adjunct Associate Professor Paul Davis developed the treatment, which uses algorithms to customise the treatment of each individual. "The treatment involves providing a pattern of sounds via music to re-train neural pathways involved in tinnitus," he said.
Tinnitus is characterised by a ringing or whistling in the ears, or buzzing and humming background sounds.
Based on 4 clinical trials on over 200 subjects, up to 90 per cent of patients currently undergoing the treatment have reported a clinically significant reduction in tinnitus disturbance within six months.
The technology is delivered through an innovative digital processor and supported by a strong clinical program.
"Tinnitus can be a debilitating condition and affects a significant number of adults in Australia," Adjunct Associate Professor Davis said.
"Those with the condition can suffer from disturbed sleep, sensitivity to loud noises and negative impacts on their social and working life.
"In treating the condition, we are dramatically improving our patients' quality of life."
Curtin Pro-Vice Chancellor Research and Development Professor Barney Glover said the launch would highlight the importance of research and development in Australia.
"The dramatic improvements which can be achieved using this research will ensure its lasting benefits for the wider community," Professor Glover said.
"This is just one example of Curtin's ability to generate important 'public service' research while also creating a viable commercial opportunity.
"The launch really highlights the wider relevance of the University and its commitment to research and development outcomes with real life applications."